Abstract
Within the series of articles investigating the burden of rheumatoid arthritis (RA), this paper reviews the methods used for economic assessment of the RA treatments by HTA agencies and other bodies involved in cost-effectiveness analysis and the current status of the field. The overall methods, as well as the challenges, of cost-effectiveness analysis in RA are common to all chronic progressive diseases where much of the treatment benefit is delayed, while costs occur immediately. Also, as in all disabling diseases, much of the costs occur outside the health-care system, due to the rapid loss of work capacity and the need for informal care in the later stages of the disease. Thus, it is essential to adopt a long-term view and consider costs from the perspective of society, rather than the health-care service, to increase the relevance of the results for policy making.
Similar content being viewed by others
References
Scott, D., Pugner, K., Kaarela, K., et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39, 122–132 (2000)
Pincus, T., Sokka, T., Wolfe, F.: Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 44, 1234–1236 (2001)
Riise, T., Jacobsen, B., Gran, J., et al.: Total mortalilty is increased in rheumatoid arthritis. A 17 year prospective study. Clin. Rheumatol. 20, 123–127 (2001)
Yelin, E., Turpin, L., Wong, B., Rush, S.: The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J. Rheumatol. 29, 1851–1857 (2002)
Chehata, J., Hassell, A., Clarke, S., et al.: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology 40, 447–452 (2001)
Jönsson B.: Quality of life and health economics. Where is the link? Scand. J. Gastroenterol. 31(Suppl 221), 33–36 (1996)
Choi, H.K., Seeger, J.D., Kuntz, K.M.: A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J. Rheumatol. 29, 1156–1165 (2002)
Maetzel, A., Tugwell, P., Boers, M., group obotOER.: Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J. Rheumatol. 30, 891–896 (2003)
Ware, J., Sherbourne, C., McHorney, C.: The MOS 36-Item Short Form Health Survey. Med. Care 31, 247–263 (1993)
DeJong, Z., van der Heijde, D., McKenna, S., Whalley, D.: The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br. J. Rheumatol. 36, 878–883 (1997)
Torrance, G.: Measurement of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1–30 (1986)
Drummond, M., O'Brien, B., Stoddart, G., Torrance, G.: Methods for the economic evaluation of health care. Kluwer, Boston (1997)
Kobelt, G.: Health economics: introduction to economic evaluation. Office of Health Economics, London (1996)
EuroQol: Group EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990)
Dolan, P., Gudex, C., Kind, P., Williams, A.: A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics, University of York, York. Report No.: Discussion paper 138 (1995)
Torrance, G.: Measurement of health state utilities for economic appraisal. A review. J. Health Econ. 5, 1–30 (1986)
Brazier, J., Roberts, J., Deverill, M.: The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21, 271–292 (2002)
Wolfe, F., Mitchell, D., Sibley, J. et al.: The mortality of rheumatoid arthritis. Arthritis Rheum. 37, 481–494 (1994)
Symmons, D., Jones, M., Scott, D., Prior P.: Long-term mortality outcome in patients with rheumatoid arthrits: early presenters continue to do well. J. Rheumatol. 25, 1072–1077 (1998)
Wallberg-Jonsson, S., Ohlman, M., Dahlqvist S.: Cardiovascular morbidity and mortality in patients with seroposivie rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445–451 (1997)
Jacobsson, L.T., Turesson, C., Gulfe, A., et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213–1218 (2005)
Jacobsson, L.T., Turesson, C., Nilsson, J.A., et al.: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 670–675 (2007)
Kobelt, G.: Health economic issues in rheumatoid arthritis. Scand. J. Rheumatol. 35, 415–425 (2006)
Kobelt, G., Eberhardt, K., Jönsson, L., Jönsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347–356 (1999)
Kobelt, G., Jönsson, L., Lindgren, P., et al.: Modelling the Progression of rheumatoid arthritis. A two-country model to estimate costs and consequences of RA. Arthritis Rheum. 46, 2310–2319 (2002)
Guillemin, F., Briancon, S., Pourel, J.: Functional disability in rheumatoid arthritis: two different models in early and established disease. J. Rheumatol. 26, 800–804 (1992)
Aletaha, D., Smolen, J., Ward, M.M.: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. 54, 2784–2792 (2006)
Fries, J., Spitz, P., Kraines, R., Holman, H.: Measurement of patient outcome in arthritis. Arthritis Rheum. 23, 137–145 (1980)
Kobelt, G., Lindgren, P., Lindroth, Y., et al.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169–1175 (2005)
Hulsemann, J.L., Ruof, J., Zeidler, H., Mittendorf, T.: Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol. Int. 26, 704–711 (2005)
Lajas, C., Abasolo, L., Bellajdel, B., et al.: Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003)
Kobelt, G., Richard, B., Peeters, P., Sany, J.: Costs and quality of life of patients with RA in France. ACR abstract, Bone, Joint, Spine (in press) (2006)
Marra, C.A., Woolcott, J.C., Kopec, J.A., et al.: A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005)
Marra C.A., Marion S.A., Guh D.P., et al.: Not all "quality-adjusted life years" are equal. J. Clin. Epidemiol. 60, 616–624 (2007)
Thompson, M., Leighton-Read, J., Hutchings, C., et al.: The cost effectiveness of auranofin. Results of a randomized clinical trial. J. Rheumatol. 15, 35–42 (1988)
Drummond, M.F., Barbieri, M., Wong, J.B.: Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med. Decis. Making 25, 520–533 (2005)
Bansback, N.J., Regier, D.A., Ara, R., et al.: An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 65, 473–496 (2005)
Smolen, K., Kalden, J., Scott, D., et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized multicentre trial. Lancet 353, 259–266 (1999)
Emery, P., Breedveld, F., Lemmel, E., et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39, 655–665 (2000)
Strand, V., Tugwell, P., Bombardier, C., et al.: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum. 42, 1870–1878 (1999)
Kobelt, G., Lindgren, P., Young, A., Eberhardt, K.: Cost and effects of leflunomide in the UK. Eur. J. Health Econ. 3, 173–179 (2002)
Maini, R., Group tAS.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354, 1932–1939 (1999)
Kobelt, G., Jönsson, L., Young, A., Eberhardt, K.: The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42, 326–335 (2003)
Weinblatt, M., Kremer, J., Bankhurst, A., et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253–312 (1999)
Jobanputra, P., Barton, P., Bryan, S., et al.: The clinical effectiveness and cost-effectiveness of new drug treatments for rheumatoid arthritis: etanercept and infliximab. University of Birmingham, Birmingham (2004)
Barton, P., Jobanputra, P., Wilson, J., et al.: The use of modelling to evaluate new drugs for patients with chronic conditions: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol. Assess. 8, 1–91 (2004)
Kobelt, G., Eberhardt, K., Geborek, P.: TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. 63, 4–10 (2004)
Wong, J., Singh, G., Kavanough, A.: Estimating the cost-effectiveness of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400–408 (2002)
Moreland, L., Schiff, M., Baumgartner, S., et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. 130, 478–486 (1999)
Brennan, A., Bansback, N., Nixon, R., et al.: Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) (2007)
Bansback, N.J., Brennan, A., Ghatnekar, O.: Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann. Rheum. Dis. 64, 995–1002 (2005)
Klareskog, L., van der Heijde, D., de Jager, J.P., et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004)
Kobelt, G., Lindgren, P., Singh, A., Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64, 1174–1179 (2005)
Wolfe, F., Michaud, K., Pincus, T.: Do rheumatology cost-effectiveness analyses make sense?. Rheumatology 43, 4–6 (2004)
Brennan, A., Bansback, N., Reynolds, A., Conway, P.: Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43, 62–72 (2004)
Zink, A., Strangfeld, A., Schneider, M., et al.: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 54, 3399–3407 (2006)
Wong, J., Ramey, D., Singh, G.: Long-term morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum. 44, 2746–2749 (2001)
Kobelt, G., Jönsson, L., Lindqvist, E., Eberhardt, K.: Cost-effectiveness of infliximab in Sweden. ACR San Francisco. Arthritis Rheum. (Abstract 2282) (2001)
Barbieri, M., Wong, J.B., Drummond, M.: The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 23, 607–618 (2005)
Smolen, J., Breedveld, T., Burmester, G., et al.: Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann. Rheum. Dis. 59, 504–505 (2000)
Conflict of interest
This study has been funded by unrestricted grant from F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kobelt, G., Jönsson, B. The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ 8 (Suppl 2), 95–106 (2008). https://doi.org/10.1007/s10198-007-0091-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-007-0091-0